Sickle Cell Anemia Clinical Trials
Here are the 6 most popular medical studies for sickle cell anemia
Histone Deacetylase Inhibitor
Panobinostat for Sickle Cell Disease
This trial is testing a drug called panobinostat to see if it is safe and effective in treating adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor, which has been shown to increase hemoglobin F induction and inhibit cell-specific inflammation.
Popular filter options for sickle cell anemia trials
Sickle Cell Disease Clinical Trials
View 93 Sickle Cell Disease medical studies.
Small Molecule
Etavopivat for Sickle Cell Disease
This trial will evaluate the safety and clinical activity of a new drug, etavopivat, in patients with thalassemia or sickle cell disease. The goal is to see if the drug can lower the number of red blood cell transfusions required and increase hemoglobin.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Tyrosine Kinase Inhibitor
Imatinib for Sickle Cell Anemia
This trial will test the effects of imatinib on sickle red blood cells. Imatinib will be given to patients following established guidelines, and the patients' red blood cells will be examined for changes. The trial will last six months.
SCD Clinical Trials
View 86 SCD medical studies.
Small Molecule
Etavopivat for Sickle Cell Disease
This trial will evaluate the safety and clinical activity of a new drug, etavopivat, in patients with thalassemia or sickle cell disease. The goal is to see if the drug can lower the number of red blood cell transfusions required and increase hemoglobin.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Tyrosine Kinase Inhibitor
Imatinib for Sickle Cell Anemia
This trial will test the effects of imatinib on sickle red blood cells. Imatinib will be given to patients following established guidelines, and the patients' red blood cells will be examined for changes. The trial will last six months.
HbSC Positive Clinical Trials
View 6 HbSC positive medical studies.
Acupuncture for Sickle Cell Pain
This trial will study whether acupuncture is an acceptable and feasible treatment for sickle cell disease patients who are hospitalized for pain, and whether it reduces their use of opioids and has an impact on their circulating cytokines and neuropeptides.
Allosteric Activator
Mitapivat for Sickle Cell Disease
This trial will test how well mitapivat works compared to placebo in treating sickle cell disease by increasing hemoglobin levels and reducing or preventing sickle cell pain crises. The long-term effect of mitapivat will also be explored.
Phase 3 Sickle Cell Anemia Clinical Trials
View 97 phase 3 sickle cell anemia medical studies.
Gene Therapy
CTX001 for Sickle Cell Disease
This trial is testing a possible new treatment for sickle cell disease using CRISPR-Cas9 technology to modify patients' own stem cells. The goal is to improve safety and efficacy compared to current treatments.
Gene Therapy
Gene Therapy for Sickle Cell Disease
This trial is studying a gene therapy for sickle cell disease. The FDA has put a partial clinical hold on the trial for patients less than 18 years of age, which means that no new enrollment, cell collection, conditioning, or drug product infusion can be initiated in pediatric patients. The study is still open to patients 18 years of age and older.
Sickle Cell Anemia Clinical Trials With No Placebo
View 97 sickle cell anemia medical studies that do not have a placebo group.
Small Molecule
Etavopivat for Sickle Cell Disease
This trial will evaluate the safety and clinical activity of a new drug, etavopivat, in patients with thalassemia or sickle cell disease. The goal is to see if the drug can lower the number of red blood cell transfusions required and increase hemoglobin.
Carbon Dioxide for Sickle Cell Anemia
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Behavioural Intervention
Exercise for Sickle Cell Trait
This trial looks at how exercise affects people with sickle cell trait. It measures changes in the body before and after exercise to see how different biomarkers are affected. This could help explain why some people with sickle cell trait have complications after strenuous exercise.
View More Sickle Cell Anemia Trials
See another 66 medical studies focused on sickle cell anemia.
Frequently Asked Questions
Introduction to sickle cell anemia
What are the top hospitals conducting sickle cell anemia research?
In the ongoing battle against sickle cell anemia, several top hospitals are making significant strides in clinical trials. Cincinnati Children's Hospital Medical Center in Cincinnati has taken a proactive approach with three active trials dedicated to this condition. Although they have just one completed trial on record since their first investigation in 2011, their commitment to advancing sickle cell anemia research is commendable. The National Institutes of Health Clinical Center, located in Bethesda, is another major player with two ongoing trials and a total of three completed studies since initiating their first trial back in 2001.
Duke University in Durham recently joined the efforts by conducting one active clinical trial for sickle cell anemia. While they do not yet have any completed trials under their belt, their involvement marks a promising step towards understanding and treating this complex disease. Meanwhile, at the University of Florida in Gainesville, researchers are focusing on one active sickle cell anemia trial and have already achieved considerable progress with one previously conducted study dating back to 2022.
Last but not least is the Innovative Clinical Research Institute (ICRI) located in Whittier. Despite being relatively new to exploring sickle cell anemia through clinical trials, ICRI has shown dedication by currently conducting one active trial focused on this condition.
These hospitals exemplify the collective determination within the medical community to find effective treatments for individuals living with sickle cell anemia—a genetic disorder that affects red blood cells' shape and function leading to complications like chronic pain episodes known as crises or organ damage due insufficient oxygen supply.Trial data from these institutions will contribute immensely toward scientific breakthroughs aimed at improving patients' quality of life while fostering hope for better treatment options and ultimately finding a cure
Which are the best cities for sickle cell anemia clinical trials?
When it comes to sickle cell anemia clinical trials, several cities emerge as leading locations for research. Pittsburgh, Pennsylvania takes the lead with 6 active trials focusing on treatments like MitoQ and CD3/CD19 depleted leukocytes. Cincinnati, Ohio follows closely behind with 4 ongoing studies investigating Etavopivat tablets, ARU-1801, and Imatinib Mesylate. Atlanta, Georgia and Indianapolis, Indiana tie with 3 active trials each exploring treatments such as Voxelotor and Hydroxyurea. Lastly, Durham, North carolina hosts 2 active trials examining interventions like exercise and Etavopivat tablets. These cities offer individuals affected by sickle cell anemia opportunities to participate in groundbreaking clinical research that may drive advancements in care for this condition.
Which are the top treatments for sickle cell anemia being explored in clinical trials?
[Sickle cell anemia](https://www.withpower.com/clinical-trials/sickle-cell-anemia) research is making strides in the search for effective treatments. Currently, two top contenders are being explored in clinical trials: exercise and CHOICES. Exercise has shown promise with two active trials dedicated to sickle cell anemia since its first listing in 2021. Similarly, CHOICES, a newer player on the scene, is also being investigated with one ongoing trial focused specifically on sickle cell anemia since its introduction in 2022. These innovative approaches hold potential for improving outcomes and quality of life for individuals affected by this challenging condition.
What are the most recent clinical trials for sickle cell anemia?
Recent clinical trials offer hope for individuals living with sickle cell anemia, as researchers continue to explore innovative treatment options. One such trial is CTX001, a Phase 3 study that investigates its effectiveness in managing sickle cell anemia. Additionally, briquilimab has shown promise in stem cell transplant recipients with SCD in both Phase 1 and Phase 2 trials. Another exciting development is the investigation of voxelotor's potential benefits for sickle cell anemia patients through Phase 2 studies. Etavopivat tablets have also undergone evaluation during their Phase 2 trial phase. Continued research into these treatments brings optimism for improved outcomes and quality of life for those affected by sickle cell anemia.
What sickle cell anemia clinical trials were recently completed?
Recently, several clinical trials investigating potential treatments for sickle cell anemia have reached significant milestones. These trials hold promise for improving the management and outcome of this challenging condition. Notably, a trial sponsored by Global Blood Therapeutics was completed in July 2021 to evaluate the safety and efficacy of their investigational drug voxelotor. In addition, a Phase 2 trial conducted by Novartis investigating crizanlizumab's ability to reduce vaso-occlusive crises in patients with sickle cell disease was concluded in December 2020. The completion of these important studies marks crucial progress toward finding better therapies for individuals affected by sickle cell anemia.